Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × rrCLL × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 1116 Neoplasms 976 Carcinoma, Non-Small-Cell Lung 888 Prostatic Neoplasms 585 Neoplasm Metastasis 525 Leukemia, Myeloid, Acute 511 Colorectal Neoplasms 485 Melanoma 481 Lung Neoplasms 480 Multiple Myeloma 471 Pancreatic Neoplasms 380 Lymphoma 368 Ovarian Neoplasms 365 Recurrence 361 Lymphoma, Non-Hodgkin 344 Leukemia 338 Leukemia, Lymphocytic, Chronic, B-Cell 320 Precursor Cell Lymphoblastic Leukemia-Lymphoma 289 Head and Neck Neoplasms 275 Carcinoma, Renal Cell 274 Brain Neoplasms 270 Carcinoma, Hepatocellular 256 Glioblastoma 244 Myelodysplastic Syndromes 242 Lymphoma, Large B-Cell, Diffuse 240 Squamous Cell Carcinoma of Head and Neck 235 Lymphoma, Follicular 233 Colonic Neoplasms 211 Stomach Neoplasms 198 Rectal Neoplasms 185

Interventions

pembrolizumab 1 dinaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02684617 2021-03-01

KEYNOTE-155

Merck Sharp & Dohme LLC

Phase 1 Terminated

75 enrolled 17 charts

rrCLL

Data powered by HemOnc (CC BY 4.0) Colophon ⚡